BAY3427080

Phase 1Small molecule

Bayer

BAY3427080 is one of 3 small molecule programs targeting Decreased liver function. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Decreased Liver FunctionActive, not recruiting

Decreased Liver FunctionPhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Decreased Liver Function

#DrugCompanyPhaseTrials

Relistor

SSalix

Approved

—2

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

BAY3427080

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Decreased liver function1 trial

A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants

Completed· Bayer logo

Bayer·Phase 1·NCT04903821·33 enrolled

Vasomotor Symptoms1 trial

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

Completed· Bayer logo

Bayer·Phase 1/2·NCT02865538·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BAY3427080. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BAY3427080 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BAY3427080. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Bayer

BAY3427080

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Decreased liver function1 trial

Vasomotor Symptoms1 trial

References

Drug Info

Quick Facts

Related News